RxDoctor Payments Data

Michael Buschur, MD

Cardiovascular Disease · Grove City, OHNPI 1851418107

Payments from drug & device makers

$58,963in general payments, 2019–2025

Across 236 payments — averaging $249.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$41K
  • Cathworks, Inc.$8K
  • Edwards Lifesciences$4K
  • EKOS Corporation$4K
  • Penumbra, Inc.$1K
  • Novartis$261
  • plus $819 from 11 others

What the payments were for

  • Consulting fees$4,1259%
  • Speaking & faculty fees$19,72543%
  • Travel & lodging$16,52436%
  • Food & beverage$5,17411%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,963 in reported general payments places this provider in the 85th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$118,622
Medicare patients
450
Services billed
1,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban465$519,046
EntrestoSacubitril/Valsartan52$71,178
XareltoRivaroxaban60$64,539
BrilintaTicagrelor32$21,963
Repatha SureclickEvolocumab14$20,398
Metoprolol Succinate416$7,076
Atorvastatin Calcium461$6,921
Prasugrel Hcl11$4,536
Rosuvastatin Calcium172$3,570
Isosorbide Mononitrate ErIsosorbide Mononitrate179$2,828
ClopidogrelClopidogrel Bisulfate266$2,368
Carvedilol210$2,135
Losartan Potassium189$1,664
Diltiazem 24hr Er (Cd)Diltiazem Hcl61$1,660
Nitroglycerin118$1,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$98$519,046465 claims
NovartisEntresto$261$71,17852 claims
Johnson & JohnsonXarelto$31$64,53960 claims
AstraZenecaBrilinta$80$21,96332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Grove City

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →